Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I see the recent hiring of one or more Merck employees as a foreshadow of a buyout or partnership. There's no announcement of the hiring(s) from CytoDyn, another clue.
I commented more about this topic on Reddit: https://www.reddit.com/r/CYDY/comments/n1v5d8/new_hire_at_cytodyn/
Today's news: Leronlimab is having great success in the Philippines and progressing beyond Compassionate Special Permit on a patient-by-patient basis:
"The Investor is an affiliate of Iliad Research and Trading, L.P. and Streeterville Capital LLC, each of which has provided similar financing to the Company."
https://ir.stockpr.com/cytodyn/sec-filings-email/content/0001193125-21-140560/d179800d8k.htm
There's no such thing as a "Conditional EUA" since all EUA's are conditional.
The FDA makes the rules, and those who pay attention know Dr. Woodcock's thoughts about studies that do not produce "actionable results."
However, if that is the FDA's policy, why does FDA approve underpowered clinical trials, and why do sponsors conduct them?
CDC = Concerned Doctors and Citizens of the Philippines (CDC Ph).
A previous video with Dr. Nicholas was made a month ago:
CYDY to $12 this month!
I discovered a source of highly accurate technical analysis charts. His latest video is on youtube:
27 Million Reasons to Buy CYDY
CYTODYN (CYDY) SHORT INTEREST DATA
Current Short Volume: 27,043,500 shares
Previous Short Volume: 26,802,300 shares
Change Vs. Previous Month: +0.90%
Dollar Volume Sold Short: $0.00
Short Interest Ratio / Days to Cover: 4.0
Last Record Date: January 15, 2021
https://www.marketbeat.com/stocks/OTCMKTS/CYDY/short-interest/
It could have been my post yesterday on reddit:
https://www.reddit.com/r/StockMarket/comments/l559ib/another_citron_victim_cytodyn/
There's a new video about CYDY. Very bullish:
Many people (including me) believe within 60 days, CYDY's price will increase to $8-$10. If that's the case, why is this stock currently selling at approximately $5?
What is the purpose of posting the number of shares you own?
It's up to Relief to provide us with answers. Hopefully, they will at least provide timely updates.
I don't think the answer to your question is publicly available.
What concerns me is Relief's responsibility for funding SamiAir product development. Hopefully, the NeuroRX/Relief partnership is good enough to address any business issues.
This article describes the process and flaws of Remdesivir's FDA approval. It should be the starting point for an official, in-depth investigation.
https://wattsupwiththat.com/2020/10/26/remdesivir-for-covid-19-study-accidentally-proved-effectiveness-of-hydroxychloroquine/
BTW, I'm not making an argument for or against HCQ, even though I'm taking it as part of Dr. Zelenko's COVID prophylaxis protocol for high-risk patients.
Correct!
All of the links supporting my claim are contained in this message board. If you (or others) have links to support different facts, please post them.
I have no idea how the NeuroRX merger affects Relief shares.
There should be a thorough investigation of Remdesivir's FDA approval process. Many lives have been lost to COVID because of BP's greed and inappropriate influence on the FDA.
There is a revenue-sharing agreement between Relief and NeuroRX. That contract should survive NeuroRX's merger.
However, the merger does not include Relief shares. It's like if your next-door neighbor gets married, it does not affect your marital status.
The merger and NYSE listing appear to be good news for NeuroRX. Can someone explain how this benefits Relief and the impact on RLFTF's share price?
https://nypost.com/2020/08/02/relief-neurorx-rlf-100-helps-critical-covid-19-patients/
The NY Post article is dated August 2, 2020
I spoke with Dr. Yo 3.5 weeks ago. He will be well prepared for Tuesday's interview.
I am an investor in RVVTF.
Three weeks ago, after the company received approval for bucillamine's compassionate use, I contacted half a dozen prestigious medical colleagues with the news. They all responded. None of them were aware of the drug or the company. They promised, time permitting, to explore the possibilities for our drug. Coincidently, my last contact with most of them was in early February when I recommended they take NAC to minimize a COVID infection.
I also contacted 10 creators of continuing medical education programs. Of the six who replied, at least two were eager to begin making a video about bucillamine. Only two were aware of the drug before I contacted them.
I also contacted eight creators of stock market videos. Four of them knew about RVVTF and expressed a strong interest in reporting on the stock if they had news to report.
I joined this forum because I was unfamiliar with penny stocks, and not much information was available about the company. There are some great posters on this board, and I wish I could communicate with them directly. However, there is a group of posters that have no idea how to treat someone with respect. I am not going to be the target of pathetic keyboard warriors' insults. In the future, my contacts' videos will reflect anything I would have posted. The company and medical community will provide me with whatever information I need.
Here's a link to Cytodyn's videos on YouTube: https://www.youtube.com/channel/UCtHxWAOCmJFSMS1FdD6X-TQ
Where's the zinc?
The study is flawed. It used 600 mg/day of HCQ for the duration of the study, and it did not include zinc. This is like giving a soldier a gun with no bullets.
Dr. Zelenko's Covid-19 Prophylaxis Protocol calls for zinc to be taken with the HCQ:
Elemental Zinc 25mg once a day
Hydroxychloroquine (HCQ) 200mg once a day for 5 days, then once a week
Many recent (politically-influenced) studies of HCQ were designed to fail.
I've read five (or fewer) of your recent posts, and they all contain incorrect information and a negative twist. It appears your objective is to create serious doubts about buying/holding RVVTF.
If you believe what you write, why would you own shares of RVVTF? And if you don't hold shares, why are you posting?
I was responding to a disparaging report about RVVTF. My comment about a COVID vaccine was possibly misunderstood.
I am not confident an effective, safe vaccine will be available anytime soon. I'm also uncertain about the durability of the immune response.
I am doing my best to boost my immune system to prevent an infection from progressing. I will do everything possible to avoid getting vaccinated.
You've poured cold water on RVVTF with incorrect/misleading statements. The news about CMPS can increase interest in RVVTF and the entire sector. There are multiple indications for Bucillamine, and the COVID vaccines have not yet received FDA approval.
I'm interested to see how quickly the news will circulate about Bucillamine's FDA approval for compassionate care of COVID patients. It might take another few days for us to see the bulk of the impact of today's announcement.
In general, information about listed stocks spreads faster than it does for OTC stocks.
Revive Therapeutics interested me because of Bucillamine, its proposed treatment for COVID. However, we're investing in every facet of the company, and Bucillamine was their proposed treatment for gout.
While I own a considerable amount of RVVTF shares, I'm relatively uninformed about the company. Sadly, most investors know less than I know about RVVTF...
Revive Therapeutics' drug bucillamine was being repurposed as a potential new treatment for gout. What is the status of that effort?
I wish I knew as much about technical analysis as you do, but the news currently governs CYDY's stock price.
On what basis do you make these statements?
MD's are just scratching the surface of understanding COVID pathophysiology. A lot has been made of the cytokine storm, but the bradykinin storm might play a more central role.
Today, Dr. Yo posted a fascinating interview with Dr. Jacobson of Oak Ridge National Laboratory:
The complete set of results was submitted to the FDA. Cytodyn issued a press release on August 11 with highlights of the Phase 2 clinical trial (for mild-to-moderate COVID patients):
https://www.cytodyn.com/newsroom/press-releases/detail/458/cytodyn-announces-clinically-significant-top-line-results
The real test will be the Phase 3 clinical trial for critically ill patients. Data from the halfway point (195 patients) will likely be reported near the end of October after evaluation by the FDA. Corresponding highlights of top line results might be released by Cytodyn at the end of September.
The problem is that you haven't reviewed the complete set of reported results for the Phase 2 trial.
What's with the Title case? Can't you write normally? More people would read what you post.
On what basis do you make your predictions about share prices?
On what basis do you claim, "Kushner is behind this company too?"
I think the situation is based on each company's drug and management's effectiveness in bringing the drug to market.
NP's comment was carefully crafted, and I agree with your analysis.